FELIQS plans to conduct a Phase 1b/2 study of FLQ-101 (tROPhy-1 study) both in the US and Japan in the first quarter of 2025.

The integration of AI into drug submission and approval processes signifies a shift towards more efficient pharmaceutical development. The potential benefits are substantial, including faster ...

Researchers used a scalable human liver microtissue model to accurately predict the drug-induced liver injury concern of 152 ...

The new director at the FDA overseeing medical devices will confront criticisms about hasty approvals as she ushers in ...

Data breaches occur in every industry, no matter the size. In particular, the pharmaceutical industry faces daily threats to ...

The US FDA has granted fast track designation to FELIQS’ lead product FLQ-101 for preventing retinopathy of prematurity (ROP) ...

RFK Jr., a longtime anti-vaccine activist, to play a role in Trump administration and potentially influence how the FDA and ...

In October, the GRx+Biosims conference included discussions on data transparency, artificial intelligence, and collaboration ...

The path from a scientist’s initial idea to a new medicine that can save lives is a complex and often lengthy process. It ...

The U.S. Food and Drug Administration (FDA) approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ...

An analysis of SpringWorks Therapeutics, Inc., including recent FDA approval, promising sales, and future funding for ...

Pharmaceutical companies are starting to harness quantum computing to improve their research and development (R ... the regulatory approval process for new drugs. A joint study by the Cleveland ...